CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.
CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. Cancer Immunol Immunother. 2010 Jun; 59(6):851-62.